Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Dry Eye Disease (DED) Clinical Trial

Official title:
A Multicenter, Single-masked, Randomized Study to Compare the Efficacy and Safety of a New Artificial Tear Formulation (011516X) With Systane® Ultra Multidose for 90 Days in Participants With Dry Eye Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04393441
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 3
Start date	June 29, 2020
Completion date	June 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04140227` - Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)	Phase 3
Completed	`NCT04036292` - Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease	Phase 3
Completed	`NCT04139798` - Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)	Phase 3
Completed	`NCT04523142` - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004	Phase 3
Completed	`NCT03333057` - Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)	Phase 2
Completed	`NCT01998802` - Phase 3 Study of EBI-005 in Dry Eye Disease	Phase 3
Completed	`NCT05723770` - Effects of NOV03 on the Tear Film	Phase 4